Scientists Discover Why Ozempic May Not Work for some People

Why It Matters

Understanding PAM‑related GLP‑1 resistance enables clinicians to predict which patients will benefit from Ozempic and similar drugs, reducing trial‑and‑error prescribing and improving outcomes in diabetes care.

Key Takeaways

• ~10% of Type 2 diabetics carry PAM variants causing GLP‑1 resistance
• Carriers show higher GLP‑1 levels but reduced glucose‑lowering response
• HbA1c improvement half as strong in PAM variant patients on GLP‑1 drugs
• Resistance appears specific to GLP‑1 agonists, not metformin or sulfonylureas
• Longer‑acting GLP‑1 formulations may bypass genetic resistance, pending trials

Pulse Analysis

The discovery of PAM‑related GLP‑1 resistance adds a new genetic layer to diabetes treatment, complementing decades of work on insulin resistance. By pinpointing a specific enzymatic defect that raises GLP‑1 levels without enhancing its activity, researchers have explained why a sizable minority of patients fail to achieve glycemic targets with standard GLP‑1 agonist doses. This insight aligns with the broader shift toward pharmacogenomics, where drug selection is guided by a patient’s DNA rather than a one‑size‑fits‑all protocol.

From a commercial perspective, the findings could reshape prescribing patterns for blockbuster drugs like Ozempic and Wegovy. Payers and providers may soon demand genetic testing before authorizing GLP‑1 therapies, especially as the cost of these injectables remains high. Meanwhile, pharmaceutical firms have an incentive to develop longer‑acting or modified GLP‑1 molecules that can circumvent PAM‑mediated resistance, potentially opening new market segments and extending product lifecycles.

Clinicians, too, stand to benefit from a clearer decision‑making framework. Early identification of PAM variant carriers could prompt alternative strategies—such as combining GLP‑1 agonists with insulin sensitizers or opting for drugs with different mechanisms. As large trial databases already contain genetic information, further retrospective analyses could refine predictive algorithms, accelerating the move toward truly personalized diabetes care.